ArticleIndustrial psychiatry journal
The metabolic paradox of aripiprazole: Weight-neutral in monotherapy but weight-reducing as adjunctive therapy.
Article in Industrial psychiatry journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotic-induced metabolic dysfunction affects 37-63% of patients, contributing to reduced life expectancy in serious mental illness. Aripiprazole demonstrates a differential effect being weight-neutral in monotherapy but producing substantial weight reduction when combined with clozapine. This is a narrative review of clinical studies examining aripiprazole's metabolic effects across different treatment contexts, focusing on monotherapy versus adjunctive therapy combinations. Monotherapy studies consistently demonstrate aripiprazole's weight-neutral profile. However, adjunctive aripiprazole with clozapine produces dramatic weight reduction. Meta-analysis data support adjunctive aripiprazole producing -2.13 kg weight reduction, though effects appear specific to clozapine combinations. This counterintuitive finding may result from aripiprazole's complex receptor interactions addressing clozapine's high-affinity H1 and 5-HT2C receptor blockade, restoring metabolic homeostasis while preserving antipsychotic efficacy. Thus, aripiprazole combination transforms clozapine into a more viable long-term treatment by preserving superior antipsychotic efficacy while reversing metabolic dysfunction. Current evidence supports this as standard care for clozapine-treated patients with metabolic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.